Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with Sanegene Bio USA Inc., has announced the dosing of the first patient in a Phase I First-in-Human (FIH) clinical trial for their siRNA drug candidate, IBI3016. This investigational therapy targets angiotensinogen (AGT) and is being developed as a novel treatment for hypertension.
Preclinical research has shown that IBI3016 significantly lowers serum AGT protein levels and associated biomarkers (ANG I, ANG II) in hypertensive cynomolgus monkeys, leading to substantial and sustained reductions in blood pressure without the safety concern of hypotension. This trial marks a significant step in advancing the drug’s development.
In December 2023, Innovent and Sanegene Bio entered into a strategic collaboration agreement to co-develop IBI3016, with Innovent holding an exclusive option to license future development, manufacturing, and commercialization rights. The drug candidate received clearance for clinical trials in China earlier this year.- Flcube.com
